ARC 165395XX

Drug Profile

ARC 165395XX

Alternative Names: AR-C165395XX

Latest Information Update: 25 Jun 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AstraZeneca
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Type 2 diabetes mellitus

Most Recent Events

  • 01 May 2015 AstraZeneca completes a phase I trial in Type-2 diabetes mellitus in USA (NCT02367066)
  • 01 Mar 2015 Phase-I clinical trials in Type-2 diabetes mellitus in USA (PO)
  • 13 Feb 2015 AstraZeneca plans a phase I trial for Type-2 diabetes mellitus in USA (NCT02367066)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top